Can Helicobacter pylori Colonization Affect the Phosphate Binder Pill Burden in Dialysis Patients?

Korucu B., HELVACI Ö., Sadioglu R., Ozbas B., YETER H. H., DERİCİ Ü.

Therapeutic Apheresis and Dialysis, vol.24, no.4, pp.380-386, 2020 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 4
  • Publication Date: 2020
  • Doi Number: 10.1111/1744-9987.13443
  • Journal Name: Therapeutic Apheresis and Dialysis
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.380-386
  • Keywords: Helicobacter pylori, Hemodialysis, Hyperphosphatemia, Peritoneal dialysis, Phosphate binders
  • Hacettepe University Affiliated: Yes


Phosphate binder pill (PBP) burden is a significant problem in dialysis patients. Phosphate absorption through the paracellular pathway increases in relatively acidic pH. In this study, we evaluated the effect of factors contributing to duodenal pH—Helicobacter pylori (HP), proton pump inhibitors (PPIs), and NaHCO3 capsules—on PBP burden. We evaluated 255 dialysis patients with gastric biopsies and excluded patients with low Kt/V, gastrectomy, and parathyroidectomy. Patients were divided into groups and subgroups regarding HP existence, use of PPI, or NaHCO3 capsules. HP+ group had significantly higher PBP burden and PBP equivalent doses (P < 0.001; both). HP+ subgroup not using daily PPIs or NaHCO3 capsules had the highest PBP burden and PBP equivalent doses (P < 0.001; both). HP− subgroups had similar PBP and PBP equivalent doses (P = 0.446 and P = 0.382; respectively). HP colonization might affect the PBP burden in dialysis patients due to a decrease of duodenal pH.